ChemoCentryx, Inc. Announces Financial Results for the Quarter Ended September 30, 2012

MOUNTAIN VIEW, Calif., Nov. 13, 2012 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today its financial results for the three and nine months ended September 30, 2012. The Company reported a net loss of $10.1 million for the quarter ended September 30, 2012, compared to a net loss of $8.7 million during the same quarter in 2011. Cash, cash equivalents and investments totaled $128.2 million at September 30, 2012, compared to $96.1 million at December 31, 2011. The Company further announced updates on the development plan for its lead independent drug candidate, CCX140.

Back to news